FDMT vs. VIR, TARS, CGEM, NMRA, SRRK, BCRX, AUTL, IMTX, PROK, and INBX
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Vir Biotechnology (VIR), Tarsus Pharmaceuticals (TARS), Cullinan Oncology (CGEM), Neumora Therapeutics (NMRA), Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), Immatics (IMTX), ProKidney (PROK), and Inhibrx (INBX). These companies are all part of the "biological products, except diagnostic" industry.
Vir Biotechnology (NASDAQ:VIR) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.
4D Molecular Therapeutics has a net margin of -436.30% compared to 4D Molecular Therapeutics' net margin of -677.69%. Vir Biotechnology's return on equity of -26.75% beat 4D Molecular Therapeutics' return on equity.
Vir Biotechnology currently has a consensus price target of $33.57, indicating a potential upside of 245.03%. 4D Molecular Therapeutics has a consensus price target of $44.22, indicating a potential upside of 74.52%. Given 4D Molecular Therapeutics' higher probable upside, equities research analysts clearly believe Vir Biotechnology is more favorable than 4D Molecular Therapeutics.
In the previous week, 4D Molecular Therapeutics had 12 more articles in the media than Vir Biotechnology. MarketBeat recorded 13 mentions for 4D Molecular Therapeutics and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.58 beat 4D Molecular Therapeutics' score of 0.40 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.
65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vir Biotechnology received 5 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. However, 65.38% of users gave 4D Molecular Therapeutics an outperform vote while only 48.15% of users gave Vir Biotechnology an outperform vote.
Vir Biotechnology has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.94, indicating that its stock price is 194% more volatile than the S&P 500.
4D Molecular Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
4D Molecular Therapeutics beats Vir Biotechnology on 13 of the 18 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
